Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022

Retrieved on: 2022-03-08 04:02:48

Tags for this article:

Click the tags to see associated articles and topics

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022. View article details on hiswai:

Excerpt

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in ...

Article found on: www.bakersfield.com